Gregory Martini serves as Senior Vice President and Chief Financial Officer at Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a biopharmaceutical company focused on advancing therapies for gastrointestinal diseases. In this role, he leads the company's global finance organization, overseeing financial planning and analysis, accounting, treasury, tax, investor relations, and risk management. Martini plays a critical role in shaping Ironwood's financial strategy, supporting the commercialization of key products like LINZESS, and driving sustainable growth through disciplined capital allocation and operational efficiency. With over 25 years of experience in the pharmaceutical and biotechnology sectors, Martini has held progressive leadership positions at several industry leaders. Prior to joining Ironwood in 2020, he served as Vice President of Finance at Synergy Pharmaceuticals, where he spearheaded financial restructuring efforts that extended the company's runway during a pivotal growth phase. Earlier in his career, he was Director of Financial Planning and Analysis at Salix Pharmaceuticals, contributing to its successful acquisition by Valeant (now Bausch Health) in a $14.5 billion deal. His achievements include raising more than $1 billion in equity and debt financings, implementing cost-saving initiatives that boosted profitability by over 30%, and enhancing reporting systems for SEC compliance. Martini's strategic acumen has been instrumental at Ironwood, where he has navigated market volatility, optimized the balance sheet, and supported key milestones such as international expansions and R&D investments. A Certified Public Accountant, he holds an MBA from the Wharton School of the University of Pennsylvania and a BS in Accounting from New York University, bringing a blend of financial expertise and industry insight to propel Ironwood's mission forward.